Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors

被引：0
|
作者：
Rasco, Drew W.
McKean, Meredith
Haydon, Andrew Mark
Weickhardt, Andrew James
Frentzas, Sophia
Ahern, Elizabeth Stephanie
Powderly, John D., II
Wyant, Timothy
Tang, Jenny
Richards, Lori
Knickerbocker, Aron
Amit, Inbar
Ofran, Yanay
Vasselli, James Robert
机构：
[1] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] The Alfred, Melbourne, Vic, Australia
[4] Austin Hlth, Austin, Australia
[5] Monash Hlth, Melbourne, Vic, Australia
[6] Monash Univ, Melbourne, Vic, Australia
[7] Monash Med Ctr, Southern Hlth, Clayton, Qld, Australia
[8] Carolina BioOncol Inst, Huntersville, NC USA
[9] Biolojic Inc, Cambridge, MA USA
[10] Aulos Biosci Inc, Larkspur, CA USA
[11] Bioloj Design, Rehovot, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2527
引用
收藏
页数：1
相关论文
共 50 条
  • [21] PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: PART 1 RESULTS
    Friedman, Claire
    Carvajal, Richard
    Davar, Diwakar
    Castanon, Eduardo
    Ascierto, Paolo
    Calvo, Emiliano
    O'Hara, Mark
    Powell, Steven
    Shapira-Frommer, Ronnie
    Garralda, Elena
    Renouf, Daniel John
    Perets, Ruth
    Yunan, Mona
    Ravindran, Palanikumar
    Hammell, Amy
    O'Brien, Shaun
    Xu, Ke
    Wilson, Nicholas
    Jhatakia, Amy
    Mukhopadhyay, Anandaroop
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A620 - A621
  • [22] A phase Ia study of DNP002, a monoclonal antibody that binds to tumor-associated CEACAM family proteins, in patients with advanced solid tumors: Interim results from dose escalation study
    Choi, W.
    Baek, J.
    Cha, Y.
    Yun, T.
    Ahn, B-C.
    Hong, Y. S.
    Kim, J. E.
    Kim, S. Y.
    Ji, G.
    Hong, K. P.
    Kim, Y.
    Kim, T. W.
    Choi, M. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1427 - S1427
  • [23] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [24] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [25] A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies
    Papadopoulos, Kyriakos P.
    Graham, Donna M.
    Tolcher, Anthony W.
    Razak, Albiruni R. A.
    Patnaik, Amita
    Bedard, Philippe L.
    Rasco, Drew Warren
    Amaya, Alex
    Moore, Kathleen N.
    Konner, Jason A.
    Matei, Daniela
    Martin, Lainie P.
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Gao, Bo
    Kostic, Ana
    DiCioccio, A. Thomas
    Trail, Pamela
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study
    Bai, X.
    Chen, Y.
    Chen, Y.
    Liang, X.
    Wang, H.
    Sun, Y.
    Chu, Q.
    Pan, Y.
    Cui, J.
    Fang, J.
    Zhang, W.
    Xu, Q.
    Zhang, J.
    Liu, X.
    Dai, G.
    Kang, L.
    Li, N.
    Fang, M.
    Zhou, H.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 (07) : 681 - 682
  • [27] A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors
    Kotecki, Nuria
    Rottey, Sylvie
    Garralda, Elena
    de de Miguel, Maria
    Saavedra, Omar
    Boni, Valentina
    Johnson, Judit W.
    McNally, Jonathan P.
    Mathew, Mohit
    Hughes, Adam
    Murphy, Sam
    Pandya, Naimish
    CANCER RESEARCH, 2023, 83 (08)
  • [28] Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients
    Shvidel, Lev
    Braester, Andrei
    Bairey, Osnat
    Rahimi-Levene, Naomi
    Herishanu, Yair
    Tadmor, Tamar
    Klepfish, Abraham
    Ruchlemer, Rosa
    Shtalrid, Mordechai
    Berrebi, Alain
    Polliack, Aaron
    ANNALS OF HEMATOLOGY, 2012, 91 (10) : 1597 - 1602
  • [29] Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients
    Lev Shvidel
    Andrei Braester
    Osnat Bairey
    Naomi Rahimi-Levene
    Yair Herishanu
    Tamar Tadmor
    Abraham Klepfish
    Rosa Ruchlemer
    Mordechai Shtalrid
    Alain Berrebi
    Aaron Polliack
    Annals of Hematology, 2012, 91 : 1597 - 1602
  • [30] Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies
    Jonasch, Eric
    Call, Justin
    Kambhampati, Swetha
    Caimi, Paolo
    Curti, Brendan
    Diefenbach, Catherine
    Heath, Elisabeth
    Park, Steven
    Kornblum, Noah
    Li, Weidong
    Reimers, Melissa
    Spurgeon, Stephen
    Vaishampayan, Ulka
    Ye, Dingwei
    Zhang, Li
    Zhao, Weili
    Chen, Zhu
    Hunder, Naomi
    Ma, Sharon
    Song, Eric
    Garmezy, Benjamin
    ONCOLOGIST, 2023, 28
12345